AACR Annual Meeting
“A Comparative Evaluation of Immunotherapy Responses in Murine Colon Carcinoma”
Introduction and Background
- With the drive in oncology to develop molecules targeting the immune system, there is a need for reliable and well-characterized preclinical models.
- The focus of immuno-oncology drug development has shifted to combination strategies with approved immunotherapies, immunometabolism targets, and costimulatory molecules.
- To better understand the utility of these agents in preclinical development, we examined the response of CT26 to combinations with anti-mPD-1, a panel of costimulatory molecules, and epacadostat, an IDO inhibitor, using in vivo tumor growth delay studies.
- Knowledge of immune composition and localization can help guide rational monotherapy and combination strategies. Investigation into these parameters are also contained in this body of work.